Dysmenorrhea Treatment Market

The secondary research process involved comprehensive analysis of regulatory databases, peer-reviewed medical journals, clinical publications, and authoritative health organizations. Key sources included the US Food & Drug Administration (FDA), European Medicines Agency (EMA), World Health Organization (WHO) Global Health Observatory, National Institutes of Health (NIH), National Center for Biotechnology Information (NCBI/PubMed), Centers for Disease Control and Prevention (CDC), American College of Obstetricians and Gynecologists (ACOG), Royal College of Obstetricians and Gynaecologists (RCOG), International Federation of Gynecology and Obstetrics (FIGO), American Society of Reproductive Medicine (ASRM), European Society of Human Reproduction and Embryology (ESHRE), Office on Women's Health (OWH), National Health Service (NHS) England, Organisation for Economic Co-operation and Development (OECD) Health Statistics, World Bank Health, Nutrition and Population Statistics, IQVIA Institute for Human Data Science, IMS Health (IQVIA) Pharmaceutical Market Data, Global Burden of Disease Study (IHME), and national health ministry reports from key markets including the US, UK, Germany, France, Japan, China, and India. These sources were used to collect epidemiological data on primary and secondary dysmenorrhea prevalence, regulatory approval data for pain relievers (NSAIDs, COX-2 inhibitors), hormonal therapies (oral contraceptives, GnRH agonists), and surgical interventions, clinical safety studies, demographic trends, treatment guidelines, and market landscape analysis across North America, Europe, Asia-Pacific, and Rest of World.

In order to gather both qualitative and quantitative insights, supply-side and demand-side stakeholders were interviewed during the primary research process. CEOs, VPs of Product Development, heads of regulatory affairs, and commercial directors from pharmaceutical companies that specialize in pain management medications, hormonal therapy manufacturers, and women's health medicines were examples of supply-side sources. Board-certified obstetricians and gynecologists, reproductive medicine specialists, doctors who treat pain, hospital pharmacy directors, medical directors of women's health clinics, and procurement leads from hospitals, gynecology clinics, fertility centers, and academic medical centers were among the demand-side sources. Primary research obtained information on clinical adoption patterns, pricing strategies, reimbursement dynamics, and patient compliance rates. It also verified product pipeline timelines for novel non-hormonal and hormonal therapies and validated market segmentation across primary dysmenorrhea and secondary dysmenorrhea categories.

Primary Respondent Breakdown:

By Designation: C-level Primaries (32%), Director Level (31%), Others (37%)

By Region: North America (38%), Europe (29%), Asia-Pacific (28%), Rest of World (5%)

Global market valuation was derived through revenue mapping and treatment volume analysis across pain relievers, hormonal therapy, and surgical segments. The methodology included:

Identification of 35+ key pharmaceutical manufacturers and medical device companies across North America, Europe, Asia-Pacific, and Latin America specializing in dysmenorrhea therapeutics

Product mapping across NSAIDs (ibuprofen, naproxen, mefenamic acid), hormonal therapies (combined oral contraceptives, progestins, GnRH agonists, levonorgestrel IUDs), and surgical interventions (laparoscopy, hysterectomy)

Analysis of reported and modeled annual revenues specific to dysmenorrhea and women's health portfolios

Coverage of manufacturers representing 75-80% of global market share in 2024

Extrapolation using bottom-up (treatment volume × ASP by country/region) and top-down (manufacturer revenue validation) approaches to derive segment-specific valuations for primary dysmenorrhea and secondary dysmenorrhea treatment markets